Compare · BDX vs KMTS
BDX vs KMTS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 32.8x KMTS ($1.58B).
- KMTS has been more active in the news (19 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 9 for KMTS).
- Company
- Becton Dickinson and Company
- Kestra Medical Technologies Ltd.
- Price
- -
- -
- Market cap
- $51.69B
- $1.58B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 19
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest KMTS
- Officer Webster Brian Daniel sold $412,180 worth of shares (15,000 units at $27.48) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 460,215 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.
- Chief Financial Officer Mahboob Vaseem sold $680,383 worth of shares (26,287 units at $25.88) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 60,609 units (SEC Form 4)
- Analyst initiated coverage on Kestra Medical Technologies with a new price target
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- Chief Commercial Officer Ford Alfred J Jr sold $151,141 worth of shares (6,275 units at $24.09), decreasing direct ownership by 6% to 99,564 units (SEC Form 4) (tax liability)
- Chief Financial Officer Mahboob Vaseem sold $172,635 worth of shares (6,995 units at $24.68) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 86,896 units (SEC Form 4) (withholding tax)
- Officer Umberger Traci S sold $86,073 worth of shares (3,580 units at $24.04), decreasing direct ownership by 2% to 195,825 units (SEC Form 4) (tax withholding)
- Officer Webster Brian Daniel sold $1,272,588 worth of shares (51,900 units at $24.52), decreasing direct ownership by 10% to 475,215 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Kestra Medical Technologies Ltd.